PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of eidLink to Publisher's site
 
Emerg Infect Dis. Mar 2003; 9(3): 404–405.
PMCID: PMC2958544
Multidrug-Resistant Shigella dysenteriae Type 1: Forerunners of a New Epidemic Strain in Eastern India?
Dipika Sur,corresponding author* Swapan K. Niyogi,* Shravani Sur, Kamal K. Datta,* Yoshifumi Takeda, Gopinath Balakrish Nair,§ and Sujit K. Bhattacharya*
*National Institute of Cholera and Enteric Diseases, Kolkata, India
Burdwan Medical College, Burdwan, West Bengal
Jissen Women’s University, Tokyo, Japan
§International Centre for Diarrhoeal Diseases Research, Dhaka, Bangladesh
corresponding authorCorresponding author.
Address for correspondence: Dipika Sur, National Institute of Cholera and Enteric Diseases, P-33 C.I.T. Road, Scheme XM, Beliaghata, Kolkata 700010, India; fax: +91 33 2350 5066; e-mail: dipikasur/at/hotmail.com
To the Editor: Multidrug-resistant Shigella dysenteriae type 1 caused an extensive epidemic of shigellosis in eastern India in 1984 (1). These strains were, however, sensitive to nalidixic acid, and clinicians found excellent results by using it to treat bacillary dysentery cases. Subsequently, in 1988 in Tripura, an eastern Indian state, a similar outbreak of shigellosis occurred in which the isolated strains of S. dysenteriae type 1 were even resistant to nalidixic acid (2). Since then, few cases of shigellosis have occurred in this region, and S. dysenteriae type 1 strains are scarcely encountered (3). In other regions of the world, especially in Southeast Asia, low-level resistance to fluoroquinolones in Shigella spp. has been observed for some time (4,5).
After a lapse of almost 14 years, clusters of patients with acute bacillary dysentery were seen at the subdivisional hospital, Diamond Harbour, in eastern India. No cases of dysentery had been reported during the comparable period in previous years. A total of 1,124 case-patients were admitted from March through June 2002. The startling feature of these infections was their unresponsiveness to even the newer fluoroquinolones such as norfloxacin and ciprofloxacin, the drugs often used to treat shigellosis. Clinicians tried various antibiotics, mostly in combinations, without benefit. Clinicians also randomly used anti-amoebic drugs without success.
An investigating team collected nine fresh fecal samples from dysentery patients admitted to this hospital; 4 (44%) yielded S. dysenteriae type 1 on culture. For isolation of Shigella spp., stool samples were inoculated into MacConkey agar and Hektoen Enteric agar (Difco, Detroit, MI), and the characteristic colonies were identified by standard biochemical methods (6). Subsequently, serogroups and serotypes were determined by visual inspection of slide agglutination tests with commercial antisera (Denka Seiken, Tokyo). Antimicrobial susceptibility testing was performed by an agar diffusion disk method, as recommended by the National Committee for Clinical Laboratory Standards (7). Results showed that the organisms were resistant to all commonly used antibiotics, including the fluoroquinolones (norfloxacin and ciprofloxacin) but were sensitive to ofloxacin. On our advice, the clinicians used ofloxacin with good results.
A similar outbreak of S. dysenteriae type 1 occurred in the northern part of West Bengal in eastern India among tea garden laborers from April 2002 to May 2002; 1,728 persons were affected (attack rate of 25.6%). Sixteen persons died. The isolated S. dysenteriae type 1 strains were found intermediately sensitive to fluroquinolones with an MIC of 2 μg/mL (K. Sarkar, S. Ghosh, S.K. Niyogi, S.K. Bhattacharya, pers. commun.).
This drug-resistant Shiga bacillus is highly likely to spread further and will certainly pose a major therapeutic challenge unless adequate preventive measures are immediately instituted to contain its spread. Appropriate awareness programs for the community and reorientation training for physicians and other health personnel would be helpful to prevent further transmission of these resistant organisms. Alternative drugs to treat drug-resistant cases and an effective vaccine are also needed.
1. Pal SC Epidemic bacillary dysentery in West Bengal. Lancet. 1984;1:1462. doi: 10.1016/S0140-6736(84)91948-2. [PubMed] [Cross Ref]
2. Sen D, Dutta P, Deb BC, Pal SC Nalidixic acid resistant Shigella dysenteriae type 1 in eastern India. Lancet. 1988;2:911. doi: 10.1016/S0140-6736(88)92515-9. [PubMed] [Cross Ref]
3. Niyogi SK, Mitra U, Dutta P Changing pattern of serotypes and antimicrobial susceptibility of Shigella species isolated from children in Calcutta, India. Jpn J Infect Dis. 2001;54:121–2. [PubMed]
4. Anh NT, Cam PD, Dalsgaard A Antimicrobial resistance of Shigella spp. isolated from diarrhoeal patients between 1989 and 1998 in Vietnam. Southeast Asian J Trop Med Public Health. 2001;32:856–62. [PubMed]
5. Nguyen JC, Goldstein FW Low level resistance to fluoroquinolones among Salmonella and Shigella. Clin Microbiol Infect. 2000;6:231. doi: 10.1046/j.1469-0691.2000.00060-3.x. [PubMed] [Cross Ref]
6. World Health Organization Manual for laboratory investigations of acute enteric infections. Document WHO/CDD/83.3. Geneva: the Organization; 1983.
7. National Committee for Clinical Laboratory Standards 1997: Performance standard for antimicrobial disk susceptibility tests: approved standards. 6th ed. NCCLS document M2-A6, Wayne (PA): The Committee; 1997.
Articles from Emerging Infectious Diseases are provided here courtesy of
Centers for Disease Control and Prevention